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In cross-sectional studies, chronic helminth infections have been
associated with immunological hyporesponsiveness that can affect
responses to unrelated antigens. To study the immunological effects
of deworming, we conducted a cluster-randomized, double-blind,
placebo-controlled trial in Indonesia and assigned 954 households
to receive albendazole or placebo once every 3 mo for 2 y. Helminth-
specific and nonspecific whole-blood cytokine responses were
assessed in 1,059 subjects of all ages, whereas phenotyping of
regulatory molecules was undertaken in 121 school-aged children.
All measurements were performed before and at 9 and 21 mo
after initiation of treatment. Anthelmintic treatment resulted in
significant increases in proinflammatory cytokine responses to
Plasmodium falciparum-infected red blood cells (PfRBCs) and mito-
gen, with the largest effect on TNF responses to PfRBCs at 9 mo—
estimate [95% confidence interval], 0.37 [0.21–0.53], P value over
time (Ptime) < 0.0001. Although the frequency of regulatory T cells
did not change after treatment, there was a significant decline in
the expression of the inhibitory molecule cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) on CD4+ T cells of albendazole-
treated individuals, –0.060 [–0.107 to –0.013] and –0.057 [–0.105
to –0.008] at 9 and 21 mo, respectively; Ptime = 0.017. This trial
shows the capacity of helminths to up-regulate inhibitory mole-
cules and to suppress proinflammatory immune responses in hu-
mans. This could help to explain the inferior immunological
responses to vaccines and lower prevalence of inflammatory dis-
eases in low- compared with high-income countries.
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Soil-transmitted helminths (STHs) represent the most com-mon infectious disease worldwide (1). In addition to specific
worm-associated morbidities, it has been argued that chronic
STH infections may magnify health-related burdens in commu-
nities remote from health care facilities, exacerbating anemia,
poor nutritional status, and possibly poor cognitive development
(1). However, this was not fully supported by the latest analysis
of the Cochrane database (2).
Immunologically, cellular immune hyporesponsiveness is a hall-
mark of chronic helminth infections that may allow parasites’ long-
term survival (3). The consequences of immunosuppression are
manifold with potentially major public health relevance. Immune
hyporesponsiveness could curtail effective immune responses,
thereby increasing susceptibility to pathogens, and helminths are
associated with suboptimal vaccine responses (4–6). The helminth-
related dampened immune responses might nevertheless help to
prevent immunopathology during coinfections and, possibly, aber-
rant reactivity to environmental or self-antigens (7). With respect to
the latter, there is currently much interest in the use of helminth
infections to treat allergies and autoimmune diseases, exploiting
their ability to induce immune hyporesponsiveness (8).
Suppressed lymphocyte responses were described in the 1970s
(9), but the evidence base has not moved much beyond animal
models and cross-sectional studies in humans (10). The cellular
mechanisms associated with helminth-related immune hypo-
responsiveness are not fully understood. Several regulatory cells
and molecules are thought to play an important role in the
regulatory network (3). Within T-cell responses, expansion of T-
regulatory cells (Tregs) is reported in both animal models (10)
and some human studies (11, 12). Tregs suppress helminth-
specific and bystander proliferative and proinflammatory re-
sponses. Expression of T-cell–associated molecules, including
cytotoxic T lymphocyte-associated antigen 4 (CTLA) and pro-
grammed death-1 (PD-1), may also be involved in helminth-
induced hyporesponsiveness and spillover suppression (13).
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Longitudinal studies assessing the effect of anthelmintic treat-
ment on cellular immune responsiveness are rare and either lack
placebo controls, target children only, or measure immune re-
sponses at one time point posttreatment (14–16). Moreover,
none have examined the changes in regulatory cells or molecules.
No large-scale community-based intervention studies to establish
whether helminth infections lead to immune hyporesponsiveness in
humans have been reported.
To disentangle the impact of helminths on the immune sys-
tem from other influences, we conducted a household cluster-
randomized, double-blind, placebo-controlled trial of albendazole
once every 3 mo in communities with high STH prevalence on
Flores island, Indonesia. Here we present results concerning the
effects of anthelmintic treatment on cellular immune responses.
Results
Albendazole Treatment Reduces but Does Not Eliminate Helminth
Infections. Characteristics of the study participants (n = 1,059)
are shown in Table 1. At baseline, one or more helminth species
were found in 88.7% of individuals, with hookworm being the
most prevalent (77.1% of total). The trial consort diagram with
follow-up data can be found in Fig. S1. Albendazole treatment
reduced the prevalence of geohelminths after 9 (51.9% vs. 84.1%
for placebo) and 21 mo (39.2% vs. 80% for placebo) (Table S1).
In the whole immunological study within Scientific Programme
Indonesia–Netherlands (IMMUNOSPIN) trial, the prevalence
of geohelminth infection was 87.3%, and albendazole treatment
reduced prevalence of geohelminths after 9 (51.4% vs. 82.8% for
placebo) and 21 mo (41.9% vs. 78.8% for placebo). As for the
whole IMMUNOSPIN trial, the greatest effect was on hook-
worm followed by Ascaris, whereas the effect on Trichuris
infections was less pronounced. Albendazole also reduced
intensities of hookworm and Ascaris infections, as assessed by
PCR (Fig. S2).
Helminth-Specific and Nonspecific Whole-Blood Cytokine Responses
Are Increased After Albendazole Treatment. Fig. 1 A and B shows
the effect of treatment on cytokine responses at 9 mo and 21 mo,
respectively. Regarding helminth-specific cytokines, Ascaris an-
tigen (AscAg)-induced interleukin-2 (IL-2) production was sig-
nificantly enhanced by treatment over the study period (Ptime =
0.018), with a significant increase in the treated group at
9 mo—estimate [95% confidence interval (CI)], 0.17 [0.05–0.28]
(Fig. 1A).
In response to plasmodial antigens (Plasmodium falciparum-
infected red blood cells, PfRBCs), there was an increase over
time in proinflammatory cytokine tumor necrosis factor (TNF;
Ptime < 0.0001) and IFN-gamma (IFN-γ; Ptime = 0.036) after
albendazole treatment. As shown in Fig. 1A, both TNF and IFN-γ
were significantly higher in the albendazole compared with the
placebo group at the 9-mo time point (0.37 [0.21–0.53] for TNF
and 0.14 [0.03–0.24] for IFN-γ). To get an indication of the ab-
solute changes in cytokine levels, TNF production to PfRBCs
in the two groups at the 9-mo time point is shown in Fig. 1C. The
differences in other statistically significant cytokine changes are
shown in Fig. S3. None of the significant changes in antigen-
specific responses were correlated with worm burden before
treatment (Table S2).
Regarding the general adaptive response (cytokine responses to
phytohemagglutinin, PHA), albendazole treatment significantly
increased TNF and IL-10 secretion (Ptime = 0.011 and Ptime =
0.003, respectively) over the trial period; for TNF, albendazole
treatment resulted in elevated responses at 9 mo, whereas for IL-
10 the response was significantly higher after 21 mo (for TNF at 9
mo, 0.14 [0.05–0.24], Fig. 1A; for IL-10 at 21 mo, 0.12 [0.05–0.19],
Fig. 1B). The IFN-γ and IL-2 responses to PHA were transiently
increased at 9 mo posttreatment, and PHA-induced IL-5 was
higher at the 21-mo time point, but this did not reach statistical
significance over the whole trial time period (IFN-γ Ptime = 0.076,
IL-2 Ptime = 0.11, IL-5 Ptime = 0.068; Fig. 1).
Albendazole did not affect responses to lipopolysaccharide
(LPS) (Table S3). Cytokines in unstimulated blood revealed no
treatment-related differences (Table S3). IFN-γ responses to
uninfected red blood cells (uRBCs) were not significantly dif-
ferent between treatment arms (Ptime = 0.91), however TNF
production was increased posttreatment (Ptime = 0.018). This was
only significant at 9 mo (9-mo estimate, 0.13 [0.01–0.25]; at
21 mo, –0.13 [–0.26–0.003]), although to a much lesser extent than
the response to PfRBCs.
The Enhancement of Cytokine Responses Is Not a Direct Albendazole
Effect. To rule out albendazole as a direct cause of enhanced
immune responses, we stratified the analysis on STH infection
status at baseline (Table 2). Enhanced PfRBC-induced TNF and
Table 1. Baseline characteristics of the study population
Parameter N Placebo N Albendazole
Age, mean in years (SD) 572 25.7 (18.5) 487 24.9 (18.4)
Sex, female, n (%)* 572 328 (57.3) 487 279 (57.3)
Area, rural, n (%)* 572 114 (19.9) 487 106 (21.8)
BMI >19 y old, mean (SD) 264 22.1 (4.1) 220 22.1 (3.8)
z score of BMI ≤19 y
old, mean (SD)
194 −1.15 (1.11) 386 −1.14(1.15)
Parasite infection,
n (%)*
Helminth, any spp. 322 286 (88.8) 237 210 (88.6)
Hookworm† 335 255 (76.1) 245 192 (78.4)
N. americanus† 335 252 (75.2) 245 188 (76.7)
A. duodenale† 335 25 (7.5) 245 17 (6.9)
A. lumbricoides† 335 105 (31.3) 245 80 (32.7)
S. stercoralis† 335 3 (0.9) 245 14 (5.7)
T. trichiura† 415 106 (25.5) 310 62 (20.0)
Malarial parasitaemia,
any spp.‡
567 24 (4.2) 483 24 (5.0)
P. falciparum 567 16 (2.8) 483 11 (2.3)
Plasmodium vivax 567 8 (1.4) 483 10 (2.1)
Plasmodium malariae 567 0 (0.0) 483 4 (0.8)
Cytokine production,
pg/mL, median [IQR]
LPS
TNF-α 554 743 [368−1,293] 468 769 [339−1,318]
IL-10 554 271 [163−441] 468 256 [158−406]
PHA
TNF-α 516 100 [50−222] 435 103 [50−214]
IL-10 515 76 [41−129] 435 70 [37−116]
IFN-γ 516 1,625 [584−3,983] 435 1,270 [538−4,340]
IL-2 516 23 [0−101] 432 23 [0−92]
IL-5 516 563 [309−840] 435 520 [317−829]
PfRBCs
TNF-α 299 18 [4−42] 237 14 [3−38]
IL-10 300 10 [5−19] 238 10 [5−20]
IFN-γ 300 163 [75−388] 239 176 [70−376]
IL-2 300 50 [5−125] 239 40 [5−112]
IL-5 300 14 [5−26] 239 12 [4−23]
AscAg
TNF-α 517 5 [0−15] 438 6 [0−14]
IL-10 516 7 [2−15] 438 7 [1−14]
IFN-γ 516 19 [6−47] 441 21 [7−47]
IL-2 497 38 [4−114] 426 36 [0−107]
IL-5 515 24 [9−68] 440 24 [9−63]
IQR, interquartile range.
*The number of positives (n) of the total population examined (N).
†Diagnosed by PCR.
‡Diagnosed by microscopy.
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AscAg-induced IL-2 by albendazole treatment were seen in
helminth-infected (Ptime = 0.0004 and Ptime = 0.006, respectively;
Table 2) but not in uninfected subjects (Table 2) at 9 mo post-
treatment. The effect of anthelmintic treatment on PHA-
stimulated TNF in the stratified analysis was seen at 9 mo
posttreatment in the helminth-infected individuals, but over the
trial period, this was not statistically significant (Ptime = 0.098;
Table 2, helminth-infected individuals). Corresponding back-
ground (unstimulated and uRBC-induced) cytokine responses
were not increased in either helminth-infected or -uninfected
subjects (Table S4).
Changes in Cell Counts After Albendazole Treatment Do Not Explain
Changes in Cytokine Responses. To determine whether increased
cellular responses could be explained by higher cell numbers, we
analyzed complete blood counts (CBCs) and sought associa-
tions with cytokine responses. Total leukocytes—most markedly
monocytes—were increased in the albendazole group com-
pared with placebo at 9 mo posttreatment but not subsequently
(Table S5). Leukocyte counts were positively associated with
IL-2 to AscAg, however the rest were mainly negative associa-
tions, of which the one with TNF responses to PfRBC was sig-
nificant. No association was found between monocyte numbers
and cytokine responses to any of the stimuli (Table S6). This
indicates that increased leukocyte numbers did not account for
the general enhancement of cytokine responses. Moreover, when
analysis of the treatment effect on cytokine responses was ad-
justed for leukocyte or monocyte counts, similar effect sizes were
observed. No treatment effect was noted on other hematological
parameters (Table S5).
Albendazole Does Not Affect Treg Frequencies but Does Expand CTLA-
4–Expressing CD4+ T Cells. To identify potential mechanisms of
immune hyporesponsiveness and their reversal by anthelmin-
tics, we examined Treg (defined as CD4+CD25hiFOXP3+ T cells)
as well as CD4+ cells expressing the suppressive molecules PD-1
and CTLA-4 in CD4+ T cells (Fig. 2). The frequency of Tregs did
not change in the albendazole group compared with placebo
(estimates [95% CI] at 9 mo, –0.027 [–0.090–0.036]; at 21 mo,
–0.022 [–0.089–0.046]; Ptime = 0.65; Fig. 2 B and F). Similarly,
treatment did not alter the expression of PD-1–expressing CD4+ T
cells over the whole trial period, although at 9 mo there was
a significant decrease (–0.074 [–0.145 to –0.002] and 0.015
[–0.057–0.086]; Ptime = 0.089, Fig. 2 C and G). However, the
proportion of CTLA-4–expressing CD4+ T cells decreased after
treatment and was significantly lower in the albendazole group
at both time points posttreatment (–0.060 [–0.107 to –0.013] and
–0.057 [–0.105 to –0.008], respectively; Ptime = 0.017; Fig. 2 D and
H). Similar to total CD4+ T cells, the frequency of CTLA-4–
expressing CD4+FOXP3– effector T cells decreased signifi-
cantly after treatment with albendazole (–0.07 [–0.125 to –0.015]
and –0.072 [–0.129 to –0.014], respectively; Ptime = 0.013; Fig. 2 E
and I). The absolute change in CTLA-4 expression on effector
T cells is shown in Fig. 2J.
Discussion
This is the report of a unique trial analyzing cytokine responses
as well as regulatory molecules in a community before and after
long-term anthelmintic treatment. We show that treatment of
STH infections ablates their immunosuppressive effects, en-
hancing immune responses to helminth and unrelated antigens
as well as to mitogen. Most pronounced were elevated proin-
flammatory cytokine responses after stimulation with plasmodial
antigens and mitogen. In addition, we observed a reduction in
CTLA-4–expressing CD4+ T cells in albendazole-treated chil-
dren, indicating that immuno-inhibitory mechanisms could be
affected by deworming.
The strongest effect of anthelmintic treatment was on anti-
plasmodial responses. These had not been specifically investigated
in anthelmintic treatment RCTs. However, in cross-sectional
studies examining the effect of helminths on malaria-specific cy-
tokine responses, results are inconsistent (17–19). The increase in
response to malaria antigens could be due to a concurrent increase
in malarial parasitemia in the albendazole-treated group 6 mo
after initiation of treatment (20), coincident with peak transmission
season. By performing the analysis without malaria-positive sub-
jects, we ruled out that this could explain the enhanced plasmodial-
specific cytokine responses.
With regard to immune regulation, no treatment-related
change in Treg frequencies was seen, consistent with the finding
of similar Treg frequencies in STH-infected and -uninfected
children reported from the same study area (12). The proportion
of PD-1–expressing CD4+ T cells was not significantly altered by
albendazole treatment over 2 y, although in the first year post-
treatment this was significantly lower. This is consistent with
studies that show increased PD-1 expression is associated with
helminth infections (13, 18). The significant decrease in CTLA-
4–expressing CD4+ T cells adds support to the important role of
this molecule in suppression of immune responses in general and
its suggested role in immune hyporesponsiveness induced by
helminths (21). When put in the context of the blockade of
CTLA-4 (as well as PD-1) in treatment of melanoma and other
cancers (22), these findings lend further support to the suggested
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Fig. 1. The effect of anthelminthic treatment on cytokine responses to AscAg, PfRBCs, and PHA. TNF, IFN-γ, IL-2, IL-5, and IL-10 concentrations were assessed
in supernatants of 72 h-stimulated whole-blood cultures. The values on the y axis (the spider web lines) represent the estimated outcome (beta) of the effect
of albendazole treatment on cytokine responses to PHA (blue), PfRBCs (red), and AscAg (green). By comparing the responses in the albendazole versus
placebo group, the estimates of the treatment effect in the whole study population after 9 (A) and 21 (B) mo of albendazole treatment were obtained using
linear mixed models, and positive values were plotted in a spider chart. Statistically significant estimates at 9 mo were IL-2 responses to AscAg (estimated
effect of treatment [95% CI], 0.17 [0.05–0.28]), TNF (0.37 [0.21–0.53]), and IFN-γ (0.14 [0.03–0.24]) responses to PfRBCs and TNF (0.14 [0.05–0.24]), IFN-γ
(0.10 [0.01–0.19]), and IL-2 (0.12 [0.01–0.23]) responses to PHA. At 21 mo posttreatment, PHA-induced IL-5 (0.10 [0.01–0.19]) and IL-10 (0.12 [0.05–0.19]) were
significantly enhanced. As an indication of the magnitude of change in level of cytokines that were significantly different between the placebo and
albendazole group, geometric mean and SE for TNF to PfRBCs at 9 mo (C) are given as an example.
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similarities between immunoregulation in chronic infectious
diseases and cancers (23).
Three-monthly albendazole treatment over a 2-y period did not
eliminate helminths. In earlier reports, the efficacy of one-time
single or double doses of albendazole and/or mebendazole treat-
ment has been low for Ascaris and Trichuris (24). Here we show
that this is the case even after seven doses of albendazole at three-
monthly intervals. By using a household-clustered randomization
design, repeated treatments, and observed intake, we expected a
more effective reduction in prevalence of STHs. For better
deworming results, more intensive treatment or inclusion of en-
vironmental control would be needed. However, it is clear that
even a 50% reduction in helminth infections in the community
can start to reverse immune hyporesponsiveness and that more
effective deworming might give even more pronounced immu-
nological effects.
Subsequent to the increased proinflammatory responses after
9 mo, IL-5 and IL-10 responses increased 21 mo posttreatment.
Table 2. Effect of albendazole treatment on immune responses by helminth infection status at baseline
Outcome
Effect of treatment at 9 mo Effect of treatment at 21 mo
Placebo N Albendazole N β [95%CI]* Placebo N Albendazole N β [95%CI]* Ptime
Effect of albendazole on cytokine responses in helminth-infected individuals
PHA
TNF 261 190 0.14 [0.01–0.26] 228 152 0.03 [–0.11–0.17] 0.098
IL-10 260 190 0.08 [–0.00–0.16] 227 152 0.06 [–0.03–0.15] 0.12
PfRBCs
TNF 154 106 0.42 [0.20–0.64] 133 84 −0.10 [–0.33–0.14] 0.0004
IFN-γ 155 108 0.12 [–0.02–0.26] 134 86 −0.01 [–0.19–0.16] 0.18
AscAg
IL-2 249 182 0.25 [0.10–0.41] 215 146 0.04 [–0.12–0.20] 0.006
Effect of albendazole on cytokine responses in helminth-uninfected individuals
PHA
TNF 31 19 0.02 [–0.40–0.43] 28 19 0.20 [–0.21–0.62] 0.63
IL-10 31 19 0.03 [–0.25–0.31] 28 19 0.31 [0.01–0.60] 0.12
PfRBCs
TNF 26 17 0.33 [–0.13–0.78] 22 15 0.15 [–0.38–0.67] 0.35
IFN-γ 26 17 0.34 [–0.03–0.71] 22 15 −0.00 [–0.42–0.41] 0.18
AscAg
IL-2 31 20 0.08 [–0.36–0.53] 28 19 −0.08 [–0.54–0.39] 0.83
The analysis of the effect of anthelmintic treatment was stratified based on helminth infection status at baseline. By comparing the
responses in the albendazole versus placebo group, the estimated outcome (beta) of the treatment effect after 9 and 21 mo of
albendazole treatment was obtained. N, the number of the total population examined (N). An overall P value (Ptime) is indicated for the
effect of treatment over time. Statistically significant results (P < 0.05) are given in bold.
*β (beta) and 95% CIs are based on linear mixed models.
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Fig. 2. Effect of deworming on cell subsets and marker expression. Flow cytometry was performed on PBMCs from a subset of school children. Gating
strategy is shown for (A) lymphocytes and CD4+ T cells, from which (B) CD25hiFOXP3+ Treg cell, (C) PD-1, and (D) CTLA-4 expressions on CD4+ T cells were
derived. (E) CTLA-4 expression on CD25hiFOXP3− cells was gated from B. The estimated effect of albendazole treatment is shown for the time points 9 and
21 mo after the start of treatment for percentages of CD25hiFOXP3+ (F), PD-1+ (G), and CTLA-4+ (H) of CD4+ T cells and CTLA-4+ of CD4+FOXP3– cells (I).
Estimates and β (beta) were obtained by linear mixed models; 95% CIs and overall P values over time (Ptime) are indicated. As an indication of magnitude of
change, the actual percentage of CTLA-4+ of CD4+FOXP3– cells in placebo and albendazole groups is shown at 9 mo (J).
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Stratified analyses revealed that the increased mitogen-stimulated
IL-5 and IL-10 was not specific to helminth-infected subjects,
suggesting that factors other than the elimination of hel-
minths may be responsible. This increased IL-10 response after
2 y of treatment might account for the fact that immune re-
sponses are not higher in the albendazole versus placebo at this
time point.
Enhanced cytokine responses could also be the result of a
boosted immune response due to the release of antigens from
dying or dead worms. However, the strongest increases in re-
sponses were not to worm antigen but to the unrelated malarial
antigen. Moreover, using pretreatment worm burden as a proxy
for antigen release, the modest increase seen to AscAg was not
correlated with burden of Ascaris lumbricoides at pretreatment,
nor were responses to nonrelated antigens correlated with base-
line worm burden. These findings argue that observed boosted
immune responses would not be due to release of antigens from
dying worms, which has been shown to account for part of the
increase in immune responses after treatment in schistosomiasis
(25), but rather be due to the decrease in immune regulation.
A number of factors other than reduction in helminths could
contribute to the findings of this study, such as a direct effect of
albendazole, alterations in immune cell counts, or changes in
nutrients. Albendazole has been shown to affect cytokine re-
sponses in vitro (26). The higher effect sizes in the stratified
analysis of helminth-positives than those in the total group in-
dicate that the enhancement of proinflammatory cytokine re-
sponses is unlikely to be due to albendazole directly affecting the
immune system. Immune hyporesponsiveness could stem from
alteration in cell counts and changes in nutrients essential to
functioning of the immune system (27). Although cell counts
were affected by treatment, cell numbers did not account for
cytokine responses. Because improved energy resources can
enhance immune responses, we assessed body mass index (BMI)
and fasting glucose level as proxies for nutritional status, but
these parameters were not affected by deworming (20).
Our study shows significant effects of deworming on the im-
mune system. The effects could lead to enhanced immune re-
sponses to other pathogens and vaccines. With respect to vaccines,
there is increasing concern regarding poor immunogenicity in
rural areas of developing countries (28, 29); therefore, any mea-
sure to alleviate hyporesponsiveness would have a major public
health impact. It is also important to consider the long-standing
evolutionary coexistence between humans and helminths, the
disturbance of which might lead to the emergence of pathological
conditions (30). However, for this outcome, long- rather than
short-term treatment courses are expected to reveal any clinical
impact (31). Considering this, it will be important to include im-
munological measurements in future deworming programs and
anthelmintic therapy trials to better understand and predict clini-
cal outcomes.
Methods
Study Design. The study was nested within the ImmunoSPIN trial, a double-
blind placebo-controlled trial conducted in two villages on Flores island,
Indonesia (20). All households were randomized to receive either a single dose
of 400 mg albendazole or placebo once every 3 mo for 2 y. Treatment was
allocated to households to minimize the risk of reinfection and was provided
to all household members older than 2 y, except for pregnant women,
according to Indonesian guidelines. Intake was observed by field workers.
Participants gave written informed or parental consent. The study was ap-
proved by the Ethics Committee of the Medical Faculty, University of Indo-
nesia, Jakarta and was filed by the Ethics Committee of the Leiden University
Medical Center, the Netherlands. The trial was registered as ISRCTN83830814.
Study Population. Randomization was based on 954 households in total,
comprising 2,022 (481 houses) and 1,982 (473 houses) subjects in placebo and
albendazole groups, respectively. For immunological studies, 250 households
in the main village were randomly selected, and individuals older than 4 y of
agewere invited for venous blood sampling and assessment of anthropometric
parameters. Thereby 882 individuals were included, of which 858 provided
sufficient blood forwhole-blood cultures. In the other village, 250 childrenwere
randomly selected from the total population, and children from the same
households were also included, giving 295 children in total with whole-blood
cultures. After cleaning the data (see Whole-Blood Culture and Cytokine
Measurements), at baseline 839 and 220 subjects were included from the two
areas, comprising 572 placebo- and 487 albendazole-treated individuals.
Because STH infection and associated immunological changes were antici-
pated to be most prevalent in school-age children, detailed analyses of reg-
ulatory components were only performed in this age group (4–12 y old). From a
randomized selection separate from the previously mentioned subset, 145
children were included (71 randomized for placebo; 74 for albendazole), of
which 121 (61 and 60, respectively) had sufficient numbers of cells. After 9 and
21 mo, 116 (56/60) and 107 (52/55) were followed up, respectively.
Whole-Blood Culture and Cytokine Measurements. Whole-blood was stimu-
lated in vitro as described before (32) for 24 h (LPS stimulation) and 72 h
[A. lumbricoides antigen (AscAg), PfRBCs, uRBCs, and PHA stimulations].
PfRBCs and uRBCs were prepared according to a standardized procedure (32).
AscAg was a homogenate of adult worm A. lumbricoides obtained from infected
humans. Supernatants were stored at –20 °C until quantification using Luminex
kits (Biosource) on a Liquichip 200 Workstation (Qiagen). TNF and IL-10 were
quantified in all supernatants, whereas IFN-γ, IL-2, and IL-5 were quantified only in
72-h supernatants. Samples with TNF levels ≥250 pg/mL in unstimulated blood
were excluded from the analyses, as they were considered possibly contaminated.
This cutoff value was derived from outliers in the data distribution. Cytokine
concentrations below the assay’s detectable range were replaced by half the
detection limit provided by the manufacturer.
Stool Examination by Microscopy and PCR. Stool samples were collected
annually. Trichuris trichiura was detected by microscopy after formol-
ether concentration, whereas multiplex real-time PCR detected hook-
worm (Ancylostoma duodenale, Necator americanus), A. lumbricoides, and
Strongyloides stercoralis DNA, as described previously (32).
CBCs. CBCs before and 1 y posttreatment were determined using heparinized
blood on a cell counter (Coulter Ac-T diff Analyzer, Beckman Coulter Inc.),
whereas CBCs 2 y posttreatment were determined on a Sysmex KX-21N he-
matology analyzer (PT Sysmex Indonesia). Because both heparinized and EDTA
blood samples were used at the last time point, 325 samples were tested in
parallel analysis. All outcomes were highly comparable except for thrombocyte
counts; thus, the data of all parameters but thrombocyte counts were pooled.
Flow Cytometry. Peripheral blood mononuclear cells (PBMCs) from 121 school
children were isolated by Ficoll gradient centrifugation. PBMCs were fixed
with FOXP3 Staining Buffer (eBioscience Inc.) and cryopreserved until further
analysis. After thawing, cells were permeabilized and stained with anti-CD3,
anti-CD4, anti-FOXP3, anti-CD25, anti–CTLA-4, anti–PD-1, and anti-Ki67 an-
tibodies (Table S7). Data were acquired on a FACSCanto (BD Biosciences) and
analyzed using FlowJo software (Treestar Inc.).
Statistical Analysis. Log transformation was used for cytokines [log10(con-
centration + 1)] and most flow cytometry [log10(value)] data to obtain
normally distributed variables. For children’s BMI, age-standardized z scores
were calculated according to WHO references (33). To assess treatment ef-
fects, linear mixed models were used; these are described in more detail in
Statistical Analysis of Cytokine Responses. Parameter estimates and 95% CIs
for treatment effects at 9 and 21 mo are reported. The analysis was in-
tention-to-treat and involved all participants as assigned randomly at the
start of the trial.
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